Do Kim
Stock Analyst at Piper Sandler
(2.10)
# 2,862
Out of 5,182 analysts
92
Total ratings
46.38%
Success rate
3.11%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $74.33 | -15.24% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $31.83 | +44.52% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $434.30 | -31.84% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $140.13 | -20.07% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $11.52 | +655.21% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $1.89 | +1,116.93% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $27.36 | -26.90% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $8.54 | +403.51% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $43.98 | -27.24% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.39 | +548.97% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $48.81 | -61.07% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.45 | +259.55% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $330.34 | -44.00% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $4.02 | +22,288.06% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $63.08 | -44.51% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.19 | +1,580.67% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $74.33
Upside: -15.24%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $31.83
Upside: +44.52%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $434.30
Upside: -31.84%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $140.13
Upside: -20.07%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $11.52
Upside: +655.21%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $1.89
Upside: +1,116.93%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $27.36
Upside: -26.90%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $8.54
Upside: +403.51%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $43.98
Upside: -27.24%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.39
Upside: +548.97%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $48.81
Upside: -61.07%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $4.45
Upside: +259.55%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $330.34
Upside: -44.00%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $4.02
Upside: +22,288.06%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $63.08
Upside: -44.51%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.19
Upside: +1,580.67%